Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
TransMedics exhibits strong fundamentals with 32% Q3 revenue growth, expanding profitability, international launch imminent, and key clinical trials underway. Though near-term technical momentum is bearish, medium-term growth prospects and pipeline catalysts make it a watch-for-entry hot idea.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin Compression ⢠Higher Leverage ⢠Strong Liquidity TMDX offers strong liquidity and gross margins, but weaker quarterly profitability, cash conversion, and rising leverage warrant caution despite lower valuation multiples.
Price Behavior
Key Price Behavior Insights: ⢠Above key averages ⢠Rebound underway ⢠Resistance remains Support Level: $88.00â$89.00 (stronger: $82.00â$84.00) Resistance Level: $92.22â$94.77 TMDX remains constructive above key averages after rebounding from $82.24, but a sustained break above $94.77 is needed to confirm renewed upside while $88.00â$89.00 support must hold.
Sentiment & News
Key News Insights: ⢠Expansion Strategy ⢠Margin Pressure ⢠Legal Scrutiny TransMedics' growth expansion and share rebound are tempered by earnings weakness, margin pressure, execution risk, and ongoing legal scrutiny.
AI Summary
TMDX's attractive 22%â25% growth outlook now hinges on whether kidney, logistics, and European expansion restore operating leverage and free-cash-flow conversion rather than entrench margin pressure amid higher debt, making execution milestonesânot revenue growth aloneâthe decisive catalyst.
Description
TransMedics Group is a commercial-stage medical technology company that develops and commercializes portable systems for perfusion, preservation and monitoring of donor organs to support transplantation in the U.S. and abroad. Its Organ Care System recreates near-physiologic conditions ex vivo and includes device variants for lungs, hearts and livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 25 | Jan 1 | TMDX | TransMedics Group, Inc. | TransMedics exhibits strong fundamentals with 32% Q3 revenue growth, expanding profitability, international launch imminent, and key clinical trials underway. Though near-term technical momentum is bearish, medium-term growth prospects and pipeline catalysts make it a watch-for-entry hot idea. | Closed | -4.2% |
| Sep 8 | Sep 15 | TMDX | TransMedics Group, Inc. | TransMedics delivered robust Q2 revenue (+38% YoY), raised 2025 guidance, received an FDA conditional approval for a key trial (Aug 2025), and shows strong technical momentum with clear near-term catalysts, although ongoing litigation and valuation levels advise cautious position sizing. | Closed | +8.3% |